Gelonghui, May 13 | Biomedical company Tevogen Bio rose 60.49% to $1.58 in the premarket. According to news, recently, the company completed a strategic investment, which will further accelerate the biopharmaceutical research and development process. The company says it has signed a binding investment agreement with an existing investor to secure financing of up to $50 million. The financing included a $36 million line of credit and a $14 million private placement. The funding is expected to close at the end of the second quarter.
美股异动丨Tevogen Bio盘前飙涨逾60% 获5000万美元战略投资
US stock changes丨Tevogen Bio surged more than 60% before the market and received a strategic investment of 50 million US dollars
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.